Literature DB >> 18181078

Polycystic ovary syndrome in asian women.

Ernest Hung Yu Ng1, Pak Chung Ho.   

Abstract

There is substantial heterogeneity of symptoms and signs among women with polycystic ovary syndrome (PCOS). In addition to different diagnostic criteria used, the ethnic background of women with PCOS may affect the clinical, hormonal, and metabolic characteristics of this condition. We present here studies related to the clinical, hormonal, and metabolic characteristics and response to the treatment of PCOS in Asia, which may be different from those in Western countries. It is important to take into consideration the ethnic background of patients in future studies related to PCOS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18181078     DOI: 10.1055/s-2007-992920

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  4 in total

Review 1.  The physiological basis of complementary and alternative medicines for polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Elisabet Stener-Victorin; XiaoKe Wu; Richard S Legro
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-04-12       Impact factor: 4.310

2.  Effects of drospirenone pill in Indian women with polycystic ovary syndrome.

Authors:  Sudhindra Mohan Bhattacharya; Mainak Ghosh; Nupur Nandi
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-09-01

3.  Metformin therapy in a hyperandrogenic anovulatory mutant murine model with polycystic ovarian syndrome characteristics improves oocyte maturity during superovulation.

Authors:  Mary E Sabatini; Lankai Guo; Maureen P Lynch; Joseph O Doyle; Hojoon Lee; Bo R Rueda; Aaron K Styer
Journal:  J Ovarian Res       Date:  2011-05-23       Impact factor: 4.234

4.  Changes in clinical and biochemical characteristics of polycystic ovary syndrome with advancing age.

Authors:  Sebastião Freitas de Medeiros; Márcia Marly Winck Yamamoto; Matheus Antônio Souto de Medeiros; Bruna Barcelo Barbosa; José Maria Soares; Edmund Chada Baracat
Journal:  Endocr Connect       Date:  2020-02       Impact factor: 3.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.